Published in PLoS One on March 01, 2017
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis (2011) 5.31
Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA (2010) 4.21
Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis (2010) 3.61
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res (2008) 3.50
Economic foundations of cost-effectiveness analysis. J Health Econ (1997) 3.33
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis (2015) 3.27
High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med (2011) 2.70
Bias in published cost effectiveness studies: systematic review. BMJ (2006) 2.60
International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ (2010) 2.57
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis (2015) 2.48
Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis (2011) 2.43
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ (2003) 2.30
Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine (2005) 1.97
Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health (2014) 1.94
The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine (2009) 1.94
Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine (2013) 1.94
Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med (2014) 1.84
Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis (2011) 1.64
Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine (2014) 1.50
Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci (2004) 1.36
Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine (2004) 1.33
Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine (2012) 1.31
Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry (2003) 1.27
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine (2009) 1.19
Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J (2014) 1.18
The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine (2007) 1.16
Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics (2009) 1.16
Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine (2012) 1.12
Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J (2006) 1.11
Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium. Med Decis Making (2008) 1.08
Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine (2009) 1.07
Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006). Vaccine (2006) 1.06
Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infect Dis (2010) 1.06
Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children. Pediatr Infect Dis J (2014) 1.05
Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine (2010) 1.01
Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine (2010) 0.98
The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine (2012) 0.97
Vaccination with partial knowledge of external effectiveness. Proc Natl Acad Sci U S A (2010) 0.96
Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health (2011) 0.95
Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. BMC Med (2011) 0.94
Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine (2011) 0.94
The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther (2008) 0.91
Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine (2011) 0.91
Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine (2011) 0.90
Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making (2006) 0.90
New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis (2011) 0.89
Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Rev Panam Salud Publica (2009) 0.88
Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and seasonal variability. Pharmacoeconomics (2013) 0.87
Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Health (2011) 0.87
Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis (2008) 0.86
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland. Vaccine (2012) 0.86
Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine (2002) 0.85
Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine (2006) 0.84
Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics (2014) 0.84
Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. Vaccine (2012) 0.84
Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine (2005) 0.84
Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS One (2013) 0.84
Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine (2010) 0.83
The role of cost-effectiveness in U.S. vaccination policy. N Engl J Med (2011) 0.82
Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. Pharmacoeconomics (2016) 0.82
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis (2012) 0.82
Methodological concerns with economic evaluations of meningococcal vaccines. Pharmacoeconomics (2010) 0.82
Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med (2013) 0.82
Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. BMC Public Health (2013) 0.81
Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review. Pharmacoeconomics (2011) 0.81
A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc (2013) 0.81
Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research. Int J Technol Assess Health Care (2004) 0.81
Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan. Vaccine (2012) 0.80
The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine (2011) 0.79
An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model". BMC Infect Dis (2013) 0.77
Pneumococcal conjugate vaccine: review of cost-effectiveness studies in Australia, North America and Europe. Expert Rev Pharmacoecon Outcomes Res (2008) 0.77